These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 20079359)
1. A PKC-beta inhibitor treatment reverses cardiac microvascular barrier dysfunction in diabetic rats. Wei L; Yin Z; Yuan Y; Hwang A; Lee A; Sun D; Li F; Di C; Zhang R; Cao F; Wang H Microvasc Res; 2010 Jul; 80(1):158-65. PubMed ID: 20079359 [TBL] [Abstract][Full Text] [Related]
2. A PKC-beta inhibitor protects against cardiac microvascular ischemia reperfusion injury in diabetic rats. Wei L; Sun D; Yin Z; Yuan Y; Hwang A; Zhang Y; Si R; Zhang R; Guo W; Cao F; Wang H Apoptosis; 2010 Apr; 15(4):488-98. PubMed ID: 20044781 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Connelly KA; Kelly DJ; Zhang Y; Prior DL; Advani A; Cox AJ; Thai K; Krum H; Gilbert RE Circ Heart Fail; 2009 Mar; 2(2):129-37. PubMed ID: 19808328 [TBL] [Abstract][Full Text] [Related]
4. PKCβ inhibition with ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Liu Y; Lei S; Gao X; Mao X; Wang T; Wong GT; Vanhoutte PM; Irwin MG; Xia Z Clin Sci (Lond); 2012 Feb; 122(4):161-73. PubMed ID: 21892921 [TBL] [Abstract][Full Text] [Related]
5. [Antagonism of LY333531 on high glucose induced permeability upregulation of cardiac microvascular endothelial cells]. Yin ZY; Wei LP; Hao YY; Zhang RQ; Li CY; Wang HC Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Apr; 25(4):303-5. PubMed ID: 19351495 [TBL] [Abstract][Full Text] [Related]
6. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. Koya D; Jirousek MR; Lin YW; Ishii H; Kuboki K; King GL J Clin Invest; 1997 Jul; 100(1):115-26. PubMed ID: 9202063 [TBL] [Abstract][Full Text] [Related]
7. Specific PKC βII inhibitor: one stone two birds in the treatment of diabetic foot ulcers. Das SK; Yuan YF; Li MQ Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 29440456 [TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of the Src inhibitor, dasatinib, on breakdown of the blood-retinal barrier. Kim SR; Suh W Arch Pharm Res; 2017 Feb; 40(2):197-203. PubMed ID: 27988882 [TBL] [Abstract][Full Text] [Related]
10. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Strøm C; Sander B; Klemp K; Aiello LP; Lund-Andersen H; Larsen M Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3855-8. PubMed ID: 16186374 [TBL] [Abstract][Full Text] [Related]
11. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Xu X; Zhu Q; Xia X; Zhang S; Gu Q; Luo D Curr Eye Res; 2004 Apr; 28(4):251-6. PubMed ID: 15259294 [TBL] [Abstract][Full Text] [Related]
12. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Yokota T; Ma RC; Park JY; Isshiki K; Sotiropoulos KB; Rauniyar RK; Bornfeldt KE; King GL Diabetes; 2003 Mar; 52(3):838-45. PubMed ID: 12606528 [TBL] [Abstract][Full Text] [Related]
13. PKC-dependent, burn-induced adherens junction reorganization and barrier dysfunction in pulmonary microvascular endothelial cells. Tinsley JH; Breslin JW; Teasdale NR; Yuan SY Am J Physiol Lung Cell Mol Physiol; 2005 Aug; 289(2):L217-23. PubMed ID: 15821015 [TBL] [Abstract][Full Text] [Related]
14. Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Liu Q; Chen X; Macdonnell SM; Kranias EG; Lorenz JN; Leitges M; Houser SR; Molkentin JD Circ Res; 2009 Jul; 105(2):194-200. PubMed ID: 19556521 [TBL] [Abstract][Full Text] [Related]
15. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Tuttle KR; Anderson PW Am J Kidney Dis; 2003 Sep; 42(3):456-65. PubMed ID: 12955673 [TBL] [Abstract][Full Text] [Related]
18. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2). Sheetz MJ; Aiello LP; Shahri N; Davis MD; Kles KA; Danis RP; Retina; 2011 Jun; 31(6):1053-9. PubMed ID: 21386766 [TBL] [Abstract][Full Text] [Related]
19. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Bursell SE; Takagi C; Clermont AC; Takagi H; Mori F; Ishii H; King GL Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2711-20. PubMed ID: 9418723 [TBL] [Abstract][Full Text] [Related]
20. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. PKC-DRS Study Group Diabetes; 2005 Jul; 54(7):2188-97. PubMed ID: 15983221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]